Home / Business and Economy / Convatec Boosts Growth Target on Strong Pipeline
Convatec Boosts Growth Target on Strong Pipeline
24 Feb
Summary
- Convatec raised its medium-term organic revenue growth target.
- Annual adjusted operating profit saw a rise of over 12%.
- New product launches and demand support company's growth.
Convatec has elevated its medium-term organic revenue growth forecast, signaling confidence in its strengthening medical product pipeline. The company announced an increase in this target on Tuesday, following a robust financial performance.
The British firm achieved an adjusted operating profit of $544 million for the fiscal year, a notable increase from the previous year's $485 million. This growth was propelled by consistent demand within its chronic-care offerings and the successful introduction of new products.
